Axel Gerdtsson
Papers
3
Total Citations
29
H-Index
3
About
Axel Gerdtsson is a leading urologic oncologist whose research centers on testicular cancer, with a particular focus on seminoma and the refinement of surgical treatment strategies. His major contribution lies in championing primary retroperitoneal lymph node dissection (RPLND) as a safe, effective alternative to traditional chemotherapy or radiotherapy for low-volume metastatic seminoma. In his landmark 2024 study from the Swedish Norwegian Testicular Cancer Group (SWENOTECA), cited 19 times, Gerdtsson demonstrated that RPLND can achieve excellent oncological outcomes while sparing patients the long-term toxicities of cytotoxic treatment. His 2023 collaborative work with the Cologne group (7 citations) further validated this approach for stage IIA-IIC seminomas ≤3 cm, establishing a new paradigm in testicular cancer management. By systematically proving that surgery can replace more toxic modalities in select patients, Gerdtsson’s research directly improves quality of life for young men facing this diagnosis. His work has been instrumental in shifting clinical guidelines and is widely cited by surgeons and oncologists seeking to minimize treatment-related morbidity without compromising survival.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3